Skip to main content
ABION Inc. logo

ABION Inc. — Investor Relations & Filings

Ticker · 203400 ISIN · KR7203400007 KO Professional, scientific and technical activities
Open in API
Filings indexed 409 across all filing types
Latest filing 2021-03-26 Declaration of Voting R…
Country KR South Korea
Listing KO 203400

About ABION Inc.

https://abionbio.com/en/

ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회 결과' (Annual General Meeting Results) and details the outcomes of the shareholder meeting held on March 26, 2021, including the approval of financial statements, director/auditor remuneration, and stock option grants. This falls directly under the definition of a Declaration of Voting Results & Voting Rights Announcement.
2021-03-26 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to specific executives (Choi Jun-young and Kang Yoon-soo), including the number of shares, exercise price, and vesting conditions. This type of disclosure regarding share-based compensation and capital changes falls under the category of share issues or capital changes, which is best classified as 'SHA' (Share Issue/Capital Change) within the provided schema.
2021-03-26 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to directors and employees, including exercise prices, vesting conditions, and fair value calculations. This type of disclosure regarding capital structure changes and equity-based compensation falls under the category of share issues or capital changes.
2021-03-26 Korean
사업보고서 (2020.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the 14th fiscal year (2020) of Abion Inc. It contains detailed financial information, company history, capital structure, and management details, which are characteristic of an Annual Report (10-K equivalent in the Korean market). FY 2020
2021-03-18 Korean
증권발행결과(자율공시)(제3자배정)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a third-party capital increase (share issuance) by the company Abion. It details the number of shares issued, the total amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2021-03-15 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report). It provides a summary of the audit opinion, key financial data (assets, liabilities, profit/loss), and auditor information for the company '에이비온'. While it contains financial data, it is a standard regulatory disclosure announcement regarding the receipt and submission of the audit report to the exchange, rather than the full annual report (10-K) or a standalone audit report document (AR). Given the structure and the nature of the disclosure, it fits the 'Report Publication Announcement' (RPA) category as it announces the submission of the audit report. FY 2020
2021-03-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.